HDCN Abstract:  ASN Annual Meeting -- San Diego  

Shiba M, Joki N, Nakamura M, et al.

Utility of Heart Rate Variability To Identfy High Risk Subset for Cardiovascular Disease among Patients with Chronic Kidney Disease.

ASN Annual Meeting -- San Diego
J Am Soc Nephrol (Nov) 20:394A 2009

Background: Chronic kidney disease (CKD) is well known as a risk factor for cardiovascular disease. However, relationship between those diseases is unclear. Sympathetic nerve hyperactivity in patient with CKD was reported. Therefore, we studied heart rate variability (HRV) to understand their cardiac autonomic nerve (CAN) status, and investigated the influence of it on long-term result.

Methods; We analyzed 81 cases of 24- hour recorded electrocardiograms among CKD (eGFR 60ml/min/1.73m by MDRD) patients who felt chest discomfort. Patients with hemodialysis were excluded. HRV was assessed by SDNN (standard deviation of normal to normal RR intervals; msec), LF (low frequency; ms) and HF (high frequency; ms) component. We divided them into the two groups according to the value of SDNN (<100,reduced: r-SDNN or 100,preserved: p-SDNN), and we investigated the occurrence of major adverse cardiovascular event (MACE; cardiovascular death, non-fetal myocardial infarction, congestive heart failure, and stroke) during follow-up periods.

Results; There were 21 patients (26.0%) with r- SDNN.Decreased ln HF (3.69 vs. 4.89ms,P=0.001) and ln LF (3.98 vs. 5.49ms, P<0.001) were seen in the r-SDNN group compared with p-SDNN group. The r-SDNN group had higher rate of MACE during follow-up period.

By multivariate analysis, independent predictor of MACE is r- SDNN (Hazard ratio,6.72; 95%CI,1.28-35.2; P=0.024). Conclusion: CAN dysfunction revealed by reduced HRV was seen in 26% of CKD patients. Combination of CKD and reduced HRV associated with poor prognosis. We may be able to identify the high risk patient for cardiovascular event among patients with CKD.

© Copyright 2009-2010 American Society of Nephrology.Reproduced with permission.
Until September of 2010 all ASN abstracts from the 2009 Annual Meeting are available at this link.

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.